{"id":7736,"date":"2023-09-19T19:29:45","date_gmt":"2023-09-20T02:29:45","guid":{"rendered":"https:\/\/rakuten-med.com\/us\/?post_type=stories&#038;p=7736"},"modified":"2023-11-06T22:08:31","modified_gmt":"2023-11-07T06:08:31","slug":"rakuten-medicals-2nd-rd-day-featured-the-preliminary-safety-and-efficacy-data-for-alluminox-treatment-using-asp-1929-in-combination-with-anti-pd-1-therapy","status":"publish","type":"stories","link":"https:\/\/rakuten-med.com\/us\/news\/stories\/2023\/09\/19\/7736\/","title":{"rendered":"Rakuten Medical&#8217;s 2nd R&amp;D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy"},"content":{"rendered":"<p><em>Disclaimer: Rakuten Medical\u2019s therapies based on Alluminox\u2122 platform are investigational outside of Japan.<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><iframe title=\"Rakuten Medical R&amp;D Day featuring ASP-1929-181 preliminary data\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/ykbCmMKVqXQ?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p>&nbsp;<\/p>\n<p>Rakuten Medical held its second R&amp;D Day on August 10, 2023, for an audience limited to pre-registered attendees from around the world. During the virtual event, special guest speaker, Ann M. Gillenwater, MD, Professor, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center presented the preliminary safety and efficacy results from ASP-1929-181, a Phase 1b\/2, open-label study of Alluminox treatment (photoimmunotherapy) using ASP-1929 in combination with anti-PD-1 therapy for recurrent and\/or metastatic head and neck cancer. For more information on the data, please see the replay at the end of this article or the <a href=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2023\/07\/10\/7717\/\">press release<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p>Dr. Gillenwater showcased how encouraging the preliminary ASP-1929-181 data was by stating:<\/p>\n<p>&nbsp;<\/p>\n<p><em><img decoding=\"async\" class=\"alignleft wp-image-7705\" src=\"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2023\/09\/person1-1-150x150.png\" alt=\"\" width=\"100\" height=\"100\" data-wp-editing=\"1\" \/><\/em><\/p>\n<p><em>\u201cThis is a novel approach that can be used after patients have already received standard therapies of surgery and radiation. The combination of the anti-PD-1 therapy with the photoimmunotherapy showed very promising early results and it was generally tolerated with manageable treatment-related adverse events.\u201d<\/em> <sup>1.<\/sup><\/p>\n<p>&nbsp;<\/p>\n<p><small>1. These preliminary findings may change upon completion of follow up and final data analysis.<\/small><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400\"><br \/>\nRakuten Medical\u2019s management team shared numerous business updates which include the recently announced <\/span><a href=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2023\/08\/10\/7729\/\"><span style=\"font-weight: 400\">licensing agreement with<\/span> <span style=\"font-weight: 400\">Hikma Pharmaceuticals for MENA region<\/span><\/a><span style=\"font-weight: 400\">, a Japan commercial update, <\/span><a href=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2023\/05\/22\/7713\/\"><span style=\"font-weight: 400\">the Global Phase 3 Trial of ASP-1929 in India<\/span><\/a><span style=\"font-weight: 400\"> (ASP-1929-301 \/ ClinicalTrials.gov Identifier: <\/span><a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03769506\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">NCT03769506<\/span><\/a><span style=\"font-weight: 400\"> \/ CTRI Identifier: <\/span><a href=\"https:\/\/ctri.nic.in\/Clinicaltrials\/showallp.php?mid1=84344&amp;EncHid=&amp;userName=CTRI\/2023\/05\/052728\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">CTRI\/2023\/05\/052728<\/span><\/a><span style=\"font-weight: 400\">), and <\/span><a href=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2023\/08\/02\/7727\/\"><span style=\"font-weight: 400\">the new study of its second asset RM-1995 in Japan<\/span><\/a> <span style=\"font-weight: 400\">(RM-1995-102 \/ <\/span><a href=\"https:\/\/jrct.niph.go.jp\/en-latest-detail\/jRCT2031220721\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">jRCT number: 2031220721<\/span><\/a><span style=\"font-weight: 400\">).<\/span><\/p>\n<p>&nbsp;<\/p>\n<p>Takashi Toraishi, Co-CEO and President of Rakuten Medical described the potential of its proprietary technology platform as:<\/p>\n<p>&nbsp;<\/p>\n<p><img decoding=\"async\" class=\"alignleft wp-image-7703\" src=\"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2023\/09\/person2-150x150.png\" alt=\"\" width=\"100\" height=\"100\" \/><\/p>\n<p><em><br \/>\n\u201cOur technology will generate rapid cell killing with minimal effects on surrounding tissues (based on preclinical observations). We believe that Alluminox\u2122 platform will change the paradigm of the cancer treatment as a potential fifth pillar.\u201d<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400\">Abhijit Bhatia, Chief Operating Officer of Rakuten Medical overviewed the company\u2019s growth by sharing updates on Rakuten Medical\u2019s commercial, clinical and business progress and commented:<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><img decoding=\"async\" class=\"alignleft wp-image-7704\" src=\"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2023\/09\/person3-150x150.png\" alt=\"\" width=\"100\" height=\"99\" \/><\/p>\n<p><i><span style=\"font-weight: 400\">\u201cWe have been co-creating innovation with excellent partners with the goal of bringing our technology to patients globally. We\u2019re conducting clinical trials at top institutes throughout the world. In Japan, we have a strong track record, supported by partner hospitals, providing more than 330 treatments as of August 2023.\u201d <\/span><\/i><i><sup>2<\/sup><\/i><\/p>\n<p>&nbsp;<\/p>\n<p><small>2. Rakuten Medical\u2019s therapies based on Alluminox\u2122 platform are investigational outside of Japan.<\/small><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400\">Toshiaki Suzuki, Co-Chief Medical Officer of Alluminox Treatment at Rakuten Medical highlighted the Company\u2019s collaboration with physicians in delivering Rakuten Medical\u2019s Alluminox treatment to patients in Japan safely and effectively.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><em><img decoding=\"async\" class=\"alignleft wp-image-7706\" src=\"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2023\/04\/Toshi.jpg\" alt=\"\" width=\"100\" height=\"99\" srcset=\"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2023\/04\/Toshi.jpg 256w, https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2023\/04\/Toshi-150x150.jpg 150w, https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2023\/04\/Toshi-75x75.jpg 75w\" sizes=\"(max-width: 100px) 100vw, 100px\" \/><\/em><\/p>\n<p>&nbsp;<\/p>\n<p><em>\u201cWorking closely with medical experts and societies in Japan, we created the Alluminox Certification System and Alluminox Training Program. We\u2019ve also created an AE management handbook, which is important to understand how to manage adverse event.\u201d<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400\">If you would like to view a complete replay of our second R&amp;D Day, please click the link below to register and reach out to us for password: <\/span><a href=\"https:\/\/lifescievents.com\/event\/rakuten\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">https:\/\/lifescievents.com\/event\/rakuten\/<\/span><\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Forward Looking Statements<br \/>\n<\/strong>This article contains \u201cforward looking\u201d statements as defined under the (United States) Private Securities Litigation Reform Act of 1995. These statements include various risks, uncertainties, and assumptions that may cause Rakuten Medical\u2019s business plans and results to differ from the anticipated results and expectations expressed in these statements. These \u201cforward looking statements\u201d contain information about the status and development of our products, including the Alluminox\u2122 platform, as well as other regulatory and marketing authorization efforts, the potential benefits, efficacy, and safety of therapies created using the Alluminox platform, and the status of regulatory filings. The approval and commercial success of the product may not be achieved. Forward looking statements relate to the potential benefits, efficacy, and safety of our therapies, and the status of regulatory filings. Such statements may include words such as \u201cexpect,\u201d \u201cbelieve,\u201d \u201chope,\u201d \u201cestimate,\u201d \u201clooks as though,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201csuggest,\u201d \u201cplan,\u201d \u201cstrategy,\u201d \u201cwill,\u201d and \u201cdo\u201d, and are based on our current beliefs. In addition, this press release uses terms such as \u201cimportant,\u201d \u201cnotable,\u201d and \u201cabnormal\u201d to express opinions about clinical trial data. Ongoing clinical trial studies include various risks and uncertainties, in particular, problems that arise during the manufacturing stage of our therapies, the occurrence of adverse safety events, situations in failure to demonstrate therapeutic benefits, and other various risks and uncertainties, both reasonable and unreasonable. For this reason, actual results, including regulatory approvals and uncertainties in the commercialization process of our therapies, may differ from published information. Except to the extent required by applicable law, we undertake no obligation to publicly update this or any other forward-looking statement, whether because of new information, future developments or events, changes in assumptions, changes in the factors affecting forward-looking statements. If one or more forward-looking statement(s) is updated, no inference should be drawn that additional updates will be made to those or other forward-looking statements.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Disclaimer: Rakuten Medical\u2019s therapies based on Alluminox\u2122 platform are investigational outside of Japan. &nbsp; &nbsp; Rakuten Medical held its second [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":7737,"template":"","meta":{"_acf_changed":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":""},"class_list":{"0":"post-7736","1":"stories","2":"type-stories","3":"status-publish","4":"has-post-thumbnail","6":"entry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rakuten Medical&#039;s 2nd R&amp;D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy - Rakuten Medical - To conquer cancer.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rakuten-med.com\/us\/news\/stories\/2023\/09\/19\/7736\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rakuten Medical&#039;s 2nd R&amp;D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy - Rakuten Medical - To conquer cancer.\" \/>\n<meta property=\"og:description\" content=\"Disclaimer: Rakuten Medical\u2019s therapies based on Alluminox\u2122 platform are investigational outside of Japan. &nbsp; &nbsp; Rakuten Medical held its second [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rakuten-med.com\/us\/news\/stories\/2023\/09\/19\/7736\/\" \/>\n<meta property=\"og:site_name\" content=\"Rakuten Medical - To conquer cancer.\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-07T06:08:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2023\/09\/Thumbnail_RD-Day-181-data.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/stories\\\/2023\\\/09\\\/19\\\/7736\\\/\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/stories\\\/2023\\\/09\\\/19\\\/7736\\\/\",\"name\":\"Rakuten Medical's 2nd R&amp;D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy - Rakuten Medical - To conquer cancer.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/stories\\\/2023\\\/09\\\/19\\\/7736\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/stories\\\/2023\\\/09\\\/19\\\/7736\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2023\\\/09\\\/Thumbnail_RD-Day-181-data.png\",\"datePublished\":\"2023-09-20T02:29:45+00:00\",\"dateModified\":\"2023-11-07T06:08:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/stories\\\/2023\\\/09\\\/19\\\/7736\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/stories\\\/2023\\\/09\\\/19\\\/7736\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/stories\\\/2023\\\/09\\\/19\\\/7736\\\/#primaryimage\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2023\\\/09\\\/Thumbnail_RD-Day-181-data.png\",\"contentUrl\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2023\\\/09\\\/Thumbnail_RD-Day-181-data.png\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/stories\\\/2023\\\/09\\\/19\\\/7736\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rakuten Medical&#8217;s 2nd R&amp;D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/\",\"name\":\"Rakuten Medical - To conquer cancer.\",\"description\":\"Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox\u2122TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rakuten Medical's 2nd R&amp;D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy - Rakuten Medical - To conquer cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rakuten-med.com\/us\/news\/stories\/2023\/09\/19\/7736\/","og_locale":"en_US","og_type":"article","og_title":"Rakuten Medical's 2nd R&amp;D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy - Rakuten Medical - To conquer cancer.","og_description":"Disclaimer: Rakuten Medical\u2019s therapies based on Alluminox\u2122 platform are investigational outside of Japan. &nbsp; &nbsp; Rakuten Medical held its second [&hellip;]","og_url":"https:\/\/rakuten-med.com\/us\/news\/stories\/2023\/09\/19\/7736\/","og_site_name":"Rakuten Medical - To conquer cancer.","article_modified_time":"2023-11-07T06:08:31+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2023\/09\/Thumbnail_RD-Day-181-data.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/rakuten-med.com\/us\/news\/stories\/2023\/09\/19\/7736\/","url":"https:\/\/rakuten-med.com\/us\/news\/stories\/2023\/09\/19\/7736\/","name":"Rakuten Medical's 2nd R&amp;D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy - Rakuten Medical - To conquer cancer.","isPartOf":{"@id":"https:\/\/rakuten-med.com\/us\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rakuten-med.com\/us\/news\/stories\/2023\/09\/19\/7736\/#primaryimage"},"image":{"@id":"https:\/\/rakuten-med.com\/us\/news\/stories\/2023\/09\/19\/7736\/#primaryimage"},"thumbnailUrl":"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2023\/09\/Thumbnail_RD-Day-181-data.png","datePublished":"2023-09-20T02:29:45+00:00","dateModified":"2023-11-07T06:08:31+00:00","breadcrumb":{"@id":"https:\/\/rakuten-med.com\/us\/news\/stories\/2023\/09\/19\/7736\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rakuten-med.com\/us\/news\/stories\/2023\/09\/19\/7736\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/rakuten-med.com\/us\/news\/stories\/2023\/09\/19\/7736\/#primaryimage","url":"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2023\/09\/Thumbnail_RD-Day-181-data.png","contentUrl":"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2023\/09\/Thumbnail_RD-Day-181-data.png","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/rakuten-med.com\/us\/news\/stories\/2023\/09\/19\/7736\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/rakuten-med.com\/us\/"},{"@type":"ListItem","position":2,"name":"Rakuten Medical&#8217;s 2nd R&amp;D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy"}]},{"@type":"WebSite","@id":"https:\/\/rakuten-med.com\/us\/#website","url":"https:\/\/rakuten-med.com\/us\/","name":"Rakuten Medical - To conquer cancer.","description":"Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox\u2122TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rakuten-med.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/stories\/7736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/stories"}],"about":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/types\/stories"}],"author":[{"embeddable":true,"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/users\/4"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/media\/7737"}],"wp:attachment":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/media?parent=7736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}